Celldex Therapeutics (CLDX) Change in Receivables (2010 - 2026)

Celldex Therapeutics' Change in Receivables history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 590.38% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$834000.0 (up 48.1% YoY), while the FY2025 annual figure was $1.3 million, up 168.21% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.8 million, down from $1.9 million in the prior quarter.
• The five-year high for Change in Receivables was $2.4 million in Q4 2023, with the low at -$1.8 million in Q1 2026.
• The 5-year median for Change in Receivables is $57000.0 (2022), against an average of $3625.0.
• Peak annual rise in Change in Receivables reached 1403.8% in 2023, while the deepest fall reached 719.18% in 2023.
• Celldex Therapeutics' Change in Receivables stood at $158000.0 in 2022, then soared by 1403.8% to $2.4 million in 2023, then tumbled by 106.4% to -$152000.0 in 2024, then soared by 1366.45% to $1.9 million in 2025, then tumbled by 192.73% to -$1.8 million in 2026.
• Business Quant data shows CLDX's Change in Receivables at -$1.8 million in Q1 2026, $1.9 million in Q4 2025, and -$974000.0 in Q2 2025.